Recombinant Protein Drugs

1. Front Matter

   Pages I-X

   PDF

2. Pioneers and business

   1. Front Matter

      Pages 1-1

      PDF

   2. Recombinant interferon - the 20th anniversary

      • Charles Weissmann

      Pages 3-41

   3. Combining science and business: from recombinant DNA to vaccines against hepatitis B virus

      • Peter Hans Hofschneider, Kenneth Murray

      Pages 43-64

3. First generation proteins

   1. Front Matter

      Pages 65-65

      PDF

   2. Clotting factors VIII and IX

      • George G. Brownlee, Paul L. F. Giangrande

      Pages 67-88

   3. Colony-stimulating factors: altering the practice of oncology

      • Karl Welte, Erich Platzer

      Pages 89-106

   4. Tissue-type plasminogen activator: helping patients with acute myocardial infarction

      • Désiré Collen, H. Roger Lijnen

      Pages 107-126

4. Proteins with new functions: protein engineering

   1. Front Matter

      Pages 127-127

      PDF

   2. Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy

      • Stephen D. Gillies

      Pages 129-147

5. Further improvement of protein drugs

   1. Front Matter

      Pages 149-149

      PDF

   2. Improving protein therapeutics: the evolution of the modern pharmacopoeia

      • Paul A. Burke, Scott D. Putney

      Pages 151-168

   3. Principles of gene transfer and foreign protein expression for human gene therapy

      • Theodore Friedmann

      Pages 169-180

6. Back Matter

   Pages 181-207

   PDF

Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...

• clinic
• clinical trial
• development
• drug
• drug discovery
• drugs
• future
• gene therapy
• hepatitis
• interferon
• oncology
• pharmaceutical
• protein
• protein engineering
• research

• Xantos Biomedicine, Martinsried, Germany

  Peter Buckel

Policies and ethics